Understanding Expanded Access in Clinical Trials

Expanded Access programs, also known as Compassionate Use, provide a way for patients to gain access to investigational drugs or treatments before they are approved for general medical use. In this article, we explain how Expanded Access works, who qualifies for it, and how patients can participate in such programs. We also discuss the regulatory framework that governs these programs and their potential benefits and risks.

What is Expanded Access?

Expanded Access is a regulatory pathway that allows patients with serious or life-threatening conditions to access investigational drugs, treatments, or medical devices that have not yet been approved by regulatory authorities, such as the FDA in the United States or the European Medicines Agency (EMA) in the European Union. These treatments are typically still in development, under investigation in clinical trials, or awaiting regulatory approval. Expanded Access is specifically for patients who do not qualify for a clinical trial or who need a treatment but cannot wait for it to be approved in the typical way.

How It Differs From Clinical Trials

It’s important to note that Expanded Access is different from clinical trial participation. Expanded Access is recorded as a study type on ClinicalTrials.gov, but unlike interventional or observational studies, its goal is treating patients rather than answering a research question, there is no randomization, no placebo, and no healthy volunteers. Sponsors and regulators may still collect safety data. While clinical trials are structured research studies designed to assess the safety and effectiveness of new treatments for a given disease, Expanded Access provides patients with access to these treatments outside of a trial, often because they are facing unmet medical needs.

Who Can Participate in Expanded Access Programs?

Not all patients are eligible for Expanded Access programs. There are strict guidelines and criteria that need to be met to ensure that the program is used appropriately and safely:

• Serious or Life-Threatening Conditions: Patients must have a serious or immediately life-threatening disease or condition. Examples include cancer, ALS (amyotrophic lateral sclerosis), and other serious illnesses.

• No Comparable Alternative: Expanded Access is available only when there is no comparable or satisfactory alternative therapy, meaning standard treatment protocols and clinical trials have been considered and are unsuitable or unavailable for the patient.

• Informed Consent: As with any investigational treatment, patients must provide informed consent, acknowledging that they understand the potential risks and uncertainties associated with receiving an experimental treatment.

• Eligibility Criteria Set by Sponsors: Sponsors of the investigational drugs or treatments (usually pharmaceutical companies) set eligibility requirements, ensuring the treatment is suited to the patient's condition.

• Regulatory Approval: The program must be authorized by the relevant regulatory authority (such as the FDA in the US) and approved by the Institutional Review Board (IRB) or Ethics Committee at the treating site, which review the risk-benefit analysis to ensure it is ethical to provide the treatment to the patient.

How to Get Access to Expanded Access Programs?

If you believe that Expanded Access might be a viable option for you or a loved one, here are the steps you need to follow:

• Talk to Your Doctor: The first step is to consult your treating physician or specialist. Because Expanded Access requests are submitted by a licensed physician on the patient's behalf, your doctor is in the best position to assess whether it could be appropriate for your condition, identify investigational treatments that might apply, and contact the sponsor or clinical research team.

• Contact the Sponsor: Researchers, pharmaceutical companies or medical device manufacturers that are developing the investigational product typically manage the Expanded Access program. They will have specific procedures in place for enrolling patients into their program.

• FDA or Regulatory Approval: In the US, the FDA must authorize expanded access use of an unapproved drug, and the IRB or ethics committee at the treating site must also approve the request (with limited exceptions for emergency single-patient cases). Other regions, such as the EU, have their own equivalent regulatory processes.

• Assessment of Eligibility: Once the request is submitted, the sponsor will review the patient’s medical history and condition to ensure they meet the eligibility criteria. The IRB (Institutional Review Board) or Ethics Committee will also review the case to make sure the risks do not outweigh the potential benefits. The patient can be asked for additional information at this stage.

• Agreement to Participate: If the program is approved, the patient will sign an agreement to participate, which includes providing informed consent and acknowledging the potential risks of receiving an experimental treatment.

What Are the Potential Benefits of Expanded Access?

Expanded Access offers several potential benefits, particularly for patients with life-threatening conditions. Some of the key benefits include:

• Access to New Drugs: Patients gain access to new drugs or treatments that have not yet been approved but may offer potential benefits for certain diseases where existing treatments have not been effective.

• Hope for Treatment: For patients with cancer, ALS, rare diseases, or other serious conditions, Expanded Access programs offer a chance to access experimental treatments when no other options are available.

• Safety Data Contribution: Sponsors typically collect safety information from patients in Expanded Access, which can complement what is learned in clinical trials.

• Use Alongside Standard Care: When the sponsor and treating physician agree, the investigational treatment may be used alongside the patient's existing standard-of-care regimen.

What Are the Potential Risks?

While the benefits are clear, there are risks associated with participating in an Expanded Access program, including:

• Unknown Efficacy: Since the treatments are still investigational, their efficacy is not guaranteed. There is a possibility that the treatment may not work as expected, or it may not provide relief.

• Potential Side Effects: As with any experimental drug, patients in Expanded Access programs may experience side effects that were not detected in earlier phases of clinical trials.

• Limited Access: Some Expanded Access programs are restricted in size or geography, so not everyone who qualifies will be able to participate.

• Regulatory Delays: Approval processes for Expanded Access can sometimes take time, and delays in approval can limit the timeliness of the treatment.

Making an Informed Decision

Expanded Access programs can offer a critical option for patients facing serious or life-threatening conditions, especially when no other treatments are available. For some, they represent access to new approaches that may not otherwise be possible. These programs also involve real uncertainty: because the treatments are still experimental, their effectiveness and potential side effects are not fully known.

Working closely with your healthcare provider, understanding eligibility requirements, and staying informed about how these programs are regulated can help you weigh both the potential benefits and risks and make a decision that is right for your situation.

Try our pre-screening to see whether a clinical trial may be a fit for your situation.